Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
There is substantial interest in the therapeutic potential of cannabidiol (CBD), a nonpsychoactive cannabinoid found in plants of the genus Cannabis. The goal of the current systematic review was to characterize the existing literature on this topic and to evaluate the credibility of CBD as a candidate pharmacotherapy for alcohol use disorder (AUD). Using a comprehensive search strategy, 303 unique potential articles were identified and 12 ultimately met criteria for inclusion (8 using rodent models, 3 using healthy adult volunteers, and 1 using cell culture). In both rodent and cell culture models, CBD was found to exert a neuroprotective effect against adverse alcohol consequences on the hippocampus. In rodent models, CBD was found to attenuate alcohol‐induced hepatotoxicity, specifically, alcohol‐induced steatosis. Finally, findings from preclinical rodent models also indicate that CBD attenuates cue‐elicited and stress‐elicited alcohol seeking, alcohol self‐administration, withdrawal‐induced convulsions, and impulsive discounting of delayed rewards. In human studies, CBD was well tolerated and did not interact with the subjective effects of alcohol. Collectively, given its favorable effects on alcohol‐related harms and addiction phenotypes in preclinical models, CBD appears to have promise as a candidate AUD pharmacotherapy. This is further bolstered by the absence of abuse liability and its general tolerability. A clear limitation to the literature is the paucity of human investigations. Human preclinical and clinical studies are needed to determine whether these positive effects in model systems substantively translate into clinically relevant outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabbout, R., Scheffer, I. E., Thiele, E. A., & Wright, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611618 · Cited by 1,711 · cited 2×
“These studies revealed that 14 weeks of 10 mg/kg/d or 20 mg/kg/d of Epidiolex© was efficacious in reducing seizure frequency (Devinsky et al., 2017, 2018a; Thiele et al., 2018).”
The orphan receptor GPR55 is a novel cannabinoid receptor
Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., & Greasley, P. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707460 · Cited by 1,568
Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor
Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., & Denovan‐Wright, E. M. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13250 · Cited by 1,039 · cited 1×
“Unlike THC, CBD is nonpsychoactive which may be attributed to its function as a negative allosteric modulator of CB1 and CB2 receptors (Laprairie et al., 2015; Mechoulam et al., 2007).”
Delayed reward discounting and addictive behavior: a meta-analysis
MacKillop, J., Amlung, M. T., Few, L. R., Ray, L. A., Sweet, L. H., & Munafò, M. R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2229-0 · Cited by 1,021 · cited 2×
“Impairments in impulse control are related to both alcohol use/AUD and risk of relapse (Amlung et al., 2017; MacKillop et al., 2011).”
Self-citationEffect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome
Devinsky, O., Patel, A. D., Cross, J. H., Villanueva, V., Wirrell, E. C., Privitera, M., Greenwood, S. M., Roberts, C., Checketts, D., VanLandingham, K. E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714631 · Cited by 1,015 · cited 3×
“(Devinsky et al., 2018a), although these groups were not compared statistically.”
Jonas, D. E., Amick, H. R., Feltner, C., Bobashev, G., Thomas, K., Wines, R., Kim, M. M., Shanahan, E., Gass, C. E., Rowe, C. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.3628 · Cited by 923 · cited 2×
“The FDA has approved 3 medications for treating AUD including naltrexone (both oral and intramuscular formulation), acamprosate, and disulfiram (Leggio and Lee, 2017); however, meta-analytic evidence only supports the use of acamprosate and naltrexone (Jonas et al., 2014).”
Thiele, E. A., Marsh, E. D., French, J. A., Mazurkiewicz-Beldzinska, M., Benbadis, S. R., Joshi, C., Lyons, P. D., Taylor, A., Roberts, C., Sommerville, K., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30136-3 · Cited by 905
Agonistic properties of cannabidiol at 5-HT1a receptors
Russo, E. B., Burnett, A., Hall, B., & Parker, K. K. (2005) · Neurochemical Research · doi:10.1007/s11064-005-6978-1 · Cited by 878 · cited 2×
“For instance, CBD can modulate 5-HT1A receptors (Russo et al., 2005), GPR55 (Ryberg et al.”
Cannabidiol and (−)Δ 9 -tetrahydrocannabinol are neuroprotective antioxidants
Hampson, A. J., Grimaldi, M., Axelrod, J., & Wink, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8268 · Cited by 850 · cited 2×
“CBD has demonstrated neuroprotective effects, preventing oxidative damage in an in vitro model of excitotoxicity (e.g., Hampson et al., 1998), making it a highly credible pharmacotherapy for reducing adverse alcoholrelated cognitive consequences.”
Oral topiramate for treatment of alcohol dependence: A randomised controlled trial
Johnson, B. A., Ait-Daoud, N., Bowden, C. L., DiClemente, C. C., Roache, J. D., Lawson, K., Javors, M. A., & Ma, J. Z. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13370-3 · Cited by 743
Impulsivity, frontal lobes and risk for addiction
Crews, F. T., & Boettiger, C. A. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.04.018 · Cited by 679 · cited 1×
“However, excessive alcohol use can give rise to neurodegeneration, which is a hypothesized cause of the observed cognitive and behavioral impairments noted in AUD (Crews and Boettiger, 2009).”
Amlung, M., Vedelago, L., Acker, J., Balodis, I., & MacKillop, J. (2017) · Addiction · doi:10.1111/add.13535 · Cited by 626 · cited 3×
“, 2015), and this specific form of impulsivity (delay discounting) has been robustly associated with AUD and other forms of addictive behavior (Amlung et al., 2017; MacKillop et al., 2011).”
Self-citationDiagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review
Kranzler, H. R., & Soyka, M. (2018) · JAMA · doi:10.1001/jama.2018.11406 · Cited by 580 · cited 1×
“Although a number of existing pharmacotherapies exist for AUD, suboptimal treatment outcomes remain common and the development of novel strategies remains a priority (Kranzler and Soyka, 2018; Litten et al., 2012, 2016a,b).”
Safety and side effects of cannabidiol, a Cannabis sativa constituent
Machado Bergamaschi, M., Helena Costa Queiroz, R., Waldo Zuardi, A., & Alexandre S. Crippa, J. (2011) · Current Drug Safety · doi:10.2174/157488611798280924 · Cited by 558
Topiramate for Treating Alcohol Dependence<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Johnson, B. A. (2007) · JAMA · doi:10.1001/jama.298.14.1641 · Cited by 542
Mechoulam, R., Peters, M., Murillo‐Rodriguez, E., & Hanuš, L. O. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790147 · Cited by 515 · cited 1×
“Unlike THC, CBD is nonpsychoactive which may be attributed to its function as a negative allosteric modulator of CB1 and CB2 receptors (Laprairie et al., 2015; Mechoulam et al., 2007).”
Cannabidiol, neuroprotection and neuropsychiatric disorders
Campos, A. C., Fogaça, M. V., Sonego, A. B., & Guimarães, F. S. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.033 · Cited by 446
MacKillop, J., Miranda, R., Monti, P. M., Ray, L. A., Murphy, J. G., Rohsenow, D. J., McGeary, J. E., Swift, R. M., Tidey, J. W., & Gwaltney, C. J. (2010) · Journal of Abnormal Psychology · doi:10.1037/a0017513 · Cited by 278 · cited 1×
“Individuals with SUDs are at risk of relapse due to multiple factors including susceptibility to stress, craving induced by drug contexts, and heightened anxiety (MacKillop et al., 2010; Ramo and Brown, 2008; Sinha, 2012).”
Self-citationSheffer, C., MacKillop, J., McGeary, J., Landes, R., Carter, L., Yi, R., Jones, B., Christensen, D., Stitzer, M., Jackson, L., et al. (2012) · The American Journal on Addictions · doi:10.1111/j.1521-0391.2012.00224.x · Cited by 263 · cited 2×
“Furthermore, precipitous delay discounting has been found to predict formal addiction treatment outcome (e.g., MacKillop and Kahler, 2009; Sheffer et al., 2012) and natural resolution of alcohol problems (Tucker et al.”
Self-citationMacKillop, J., & Kahler, C. W. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.04.020 · Cited by 232 · cited 1×
“Furthermore, precipitous delay discounting has been found to predict formal addiction treatment outcome (e.g., MacKillop and Kahler, 2009; Sheffer et al., 2012) and natural resolution of alcohol problems (Tucker et al., 2002, 2008).”
Self-citationTargeting the endocannabinoid system: future therapeutic strategies
Aizpurua-Olaizola, O., Elezgarai, I., Rico-Barrio, I., Zarandona, I., Etxebarria, N., & Usobiaga, A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.08.005 · Cited by 209 · cited 1×
“The eCB is an important physiological system with broad activity impacting various functions of the human body, including brain plasticity, inflammation, appetite regulation, and learning and memory among others (Aizpurua-Olaizola et al., 2017).”
Rando, K., Hong, K.-I., Bhagwagar, Z., Li, C.-S. R., Bergquist, K., Guarnaccia, J., & Sinha, R. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10020233 · Cited by 189
Palpacuer, C., Duprez, R., Huneau, A., Locher, C., Boussageon, R., Laviolle, B., & Naudet, F. (2018) · Addiction · doi:10.1111/add.13974 · Cited by 172
Agurell, S., Carlsson, S., Lindgren, J. E., Ohlsson, A., Gillespie, H., & Hollister, L. (1981) · Experientia · doi:10.1007/bf02085029 · Cited by 129
Classes of substance abuse relapse situations: A comparison of adolescents and adults.
Ramo, D. E., & Brown, S. A. (2008) · Psychology of Addictive Behaviors · doi:10.1037/0893-164x.22.3.372 · Cited by 128
Problematic alcohol use and reduced hippocampal volume: a meta-analytic review
Wilson, S., Bair, J. L., Thomas, K. M., & Iacono, W. G. (2017) · Psychological Medicine · doi:10.1017/s0033291717000721 · Cited by 90
Cited by
Cannabidiol: pharmacology and therapeutic targets
Britch, S. C., Babalonis, S., & Walsh, S. L. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05712-8 · Cited by 307
“For a review of CBD effects on alcohol consumption in animal models see Turna et al. (2019).”
BackgroundNovel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
“Evidence in healthy individuals demonstrates that CBD is well tolerated, does not interact with the subjective effects of alcohol, and has no abuse liability [280].”
BackgroundSpanagel, R. (2020) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2020.22.3/rspanagel · Cited by 127
Brancato, A., Castelli, V., Lavanco, G., Tringali, G., Micale, V., Kuchar, M., D’Amico, C., Pizzolanti, G., Feo, S., & Cannizzaro, C. (2021) · Biomedicines · doi:10.3390/biomedicines9091161 · Cited by 37
Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review
Fischler, P. V., Soyka, M., Seifritz, E., & Mutschler, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.927703 · Cited by 34
“Because the endocannabinoid system is important for regulation of emotional control andmotivational behavior,modulation of these pathways may well provide an interesting starting point for development of new medications for alcohol use disorder (Basavarajappa and Hungund, 2005; Mouslech and Valla, 2009; Maccioni et al…”
Background
Metadata
- Authors
- Turna, J., Syan, S. K., Frey, B. N., Rush, B., Costello, M. J., Weiss, M., & MacKillop, J.
- Venue
- Alcoholism: Clinical and Experimental Research
- Publisher
- Wiley
- Published
- 2019-02-19
- Volume
- 43
- Issue
- 4
- Pages
- 550-563
- ISSN
- 0145-6008 (ISSN-L)
- 1530-0277
- OpenAlex
- W2913565801
- Cited by
- 83
- References
- 26
- FWCI
- 2.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.